With its needle laser confocal endomicroscopy solution, Mauna Kea plays a decisive role in the fight against pancreatic cancer
Regulatory News:
In honor of Pancreatic Cancer Awareness Month, Mauna Kea Technologies (Euronext Growth : ALMKT) inventor of Cellvizio®the multidisciplinary miniprobe and needle confocal laser endomicroscopy (p/nCLE) platform, is raising awareness about one of the deadliest cancers by sharing patient stories and highlighting the importance of early detection.
With a five-year survival rate of just 13% and an increase in diagnoses in people under 50, there is an urgent need for action to raise awareness and promote the use of advanced diagnostic tools. A investigation recent study reveals that 83% of people do not know how to identify the first symptoms of pancreatic cancer, such as persistent abdominal or back pain, sudden onset of diabetes, unexplained weight loss or jaundice. These findings highlight a crucial gap in awareness, particularly due to the subtle and easily overlooked nature of these signs.
To meet this challenge, Mauna Kea Technologies shares the stories of patients whose lives have been transformed thanks to rapid diagnosis and innovative tools such as the Cellvizio platform® at theOhio State University Wexner Medical Center.
Discover these inspiring journeys and learn more about the symptoms of pancreatic cancer by visiting this page. These stories highlight the significant impact of early detection tools like Cellvizio®which provides real-time cellular imaging during endoscopic procedures. Cellvizio® plays a key role in accelerating accurate diagnoses, especially for patients at high risk or with indeterminate pancreatic cysts.
True to its mission to improve patient care, Mauna Kea Technologies continues to collaborate with healthcare professionals and researchers around the world to advance endomicroscopy and other diagnostic innovations.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and markets Cellvizio®the real-time in vivo cellular imaging platform. This technology provides unique in vivo cellular visualization that allows physicians to monitor disease progression over time, assess responses as they occur, classify areas of uncertainty, and guide surgical interventions. The Cellvizio platform is used in many countries around the world and in several medical specialties and is transforming the way doctors diagnose and treat patients. For more information, visit the website www.maunakeatech.com.
Warning
This release contains forward-looking statements relating to Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, without limitation, those regarding the financial condition, business, strategies, plans and objectives of management of Mauna Kea Technologies for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no guarantee can be given as to the achievement of the forecasts expressed in these forward-looking statements which are subject to numerous risks and uncertainties, including those described in Chapter 2 of the 2023 annual report of Mauna Kea Technologies filed with the Authority financial markets (AMF) on April 30, 2024, available on the Company’s website (www.maunakeatech.fr), as well as risks linked to changes in the economic situation, financial markets and the markets in which Mauna Kea Technologies is present. Forward-looking statements in this release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not believe to be material as of this date. The realization of all or any of these risks could cause the actual results, financial conditions, performance or achievements of Mauna Kea Technologies to differ materially from the results, financial conditions, performance or achievements expressed in these forward-looking statements. This press release and the information it contains constitute neither an offer to sell or subscribe, nor the solicitation of an order to purchase or subscribe for the shares of Mauna Kea Technologies in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may, in certain jurisdictions, be restricted by local regulations. Persons who come into possession of this document are responsible for complying with all local regulations applicable to this document.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20241126962587/fr/
